AstraZeneca has decided to cut its losses and drop the Phase III antidepressant candidate TC-5214 that it licensed from Targacept in December 2009.
It said that it would not pursue a regulatory filing for the novel neuronal nicotinic receptor antagonist after reporting that...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?